{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:26:25Z","timestamp":1781670385968,"version":"3.54.5"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Korea Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecules and Cells"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.mocell.2025.100193","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T16:23:15Z","timestamp":1739204595000},"page":"100193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of transcription factors in prostate cancer progression"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-2329","authenticated-orcid":false,"given":"Jongeun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6810-3087","authenticated-orcid":false,"given":"Yoontae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mocell.2025.100193_bib1","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mocell.2025.100193_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","article-title":"FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes","volume":"571","author":"Adams","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.mocell.2025.100193_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mocell.2025.100193_bib4","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib5","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib6","doi-asserted-by":"crossref","first-page":"14788","DOI":"10.1073\/pnas.1410419111","article-title":"ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers","volume":"111","author":"Augustyn","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mocell.2025.100193_bib7","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/s41467-021-22139-7","article-title":"Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer","volume":"12","author":"Baca","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mocell.2025.100193_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2019.06.005","article-title":"Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies","volume":"36","author":"Balanis","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2005.03.013","article-title":"REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis","volume":"121","author":"Ballas","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib10","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.mocell.2025.100193_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mocell.2025.100193_bib14","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer","volume":"130","author":"Beltran","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mocell.2025.100193_bib15","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1158\/1078-0432.CCR-19-0498","article-title":"BRN4 is a novel driver of neuroendocrine differentiation in castration-resistant prostate cancer and is selectively released in extracellular vesicles with BRN2","volume":"25","author":"Bhagirath","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor-suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mocell.2025.100193_bib17","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1038\/s41467-021-23780-y","article-title":"Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer","volume":"12","author":"Brady","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mocell.2025.100193_bib18","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mocell.2025.100193_bib19","doi-asserted-by":"crossref","first-page":"84863","DOI":"10.18632\/oncotarget.19386","article-title":"Implications of PI3K\/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mocell.2025.100193_bib20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature03918","article-title":"Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis","volume":"436","author":"Chen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.mocell.2025.100193_bib21","first-page":"327","article-title":"Bioinformatics analyses of publicly available NEPCa datasets","volume":"7","author":"Cheng","year":"2019","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.mocell.2025.100193_bib22","first-page":"5619","article-title":"FOXA2 promotes prostate cancer growth in the bone","volume":"12","author":"Connelly","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.mocell.2025.100193_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrurol.2018.22","article-title":"Cellular plasticity and the neuroendocrine phenotype in prostate cancer","volume":"15","author":"Davies","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.mocell.2025.100193_bib25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mocell.2025.100193_bib26","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mocell.2025.100193_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/1078-0432.CCR-18-0729","article-title":"Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer","volume":"25","author":"Flores-Morales","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ajpath.2011.10.021","article-title":"FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer","volume":"180","author":"Gerhardt","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.mocell.2025.100193_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0896-6273(03)00497-5","article-title":"SOX2 functions to maintain neural progenitor identity","volume":"39","author":"Graham","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.mocell.2025.100193_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.semcancer.2019.03.004","article-title":"The role of SOX family members in solid tumours and metastasis","volume":"67","author":"Grimm","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.mocell.2025.100193_bib31","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mocell.2025.100193_bib32","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2017.07.007","article-title":"Diagnostic characteristics of lethal prostate cancer","volume":"84","author":"Helgstrand","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.mocell.2025.100193_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2559.2011.04039.x","article-title":"Histological variants of prostatic carcinoma and their significance","volume":"60","author":"Humphrey","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.mocell.2025.100193_bib35","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/pros.23874","article-title":"Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion","volume":"79","author":"Kaipainen","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.mocell.2025.100193_bib36","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1158\/1078-0432.CCR-20-4968","article-title":"BET bromodomain inhibition blocks an AR-repressed, E2F1-activated treatment-emergent neuroendocrine prostate cancer lineage plasticity program","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib37","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/onc.2017.50","article-title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.mocell.2025.100193_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.mocell.2025.100193_bib39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.trecan.2019.05.008","article-title":"Clonal evolution and epithelial plasticity in the emergence of AR-independent prostate carcinoma","volume":"5","author":"Laudato","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.mocell.2025.100193_bib40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib41","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2016.04.028","article-title":"SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition","volume":"71","author":"Li","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mocell.2025.100193_bib42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/path.5557","article-title":"Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2","volume":"253","author":"Liu","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.mocell.2025.100193_bib43","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1172\/JCI135373","article-title":"LIN28B promotes the development of neuroendocrine prostate cancer","volume":"130","author":"Lovnicki","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mocell.2025.100193_bib44","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1002\/jcp.29267","article-title":"Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide","volume":"235","author":"Metz","year":"2020","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.mocell.2025.100193_bib45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/pros.20299","article-title":"Expression and role of Foxa proteins in prostate cancer","volume":"66","author":"Mirosevich","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.mocell.2025.100193_bib46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.mocell.2025.100193_bib47","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0022-5347(01)62136-0","article-title":"p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential","volume":"161","author":"Navone","year":"1999","journal-title":"J. Urol."},{"key":"10.1016\/j.mocell.2025.100193_bib48","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41467-022-29963-5","article-title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer","volume":"13","author":"Nouruzi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mocell.2025.100193_bib49","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2019.08.007","article-title":"SOX2 in development and cancer biology","volume":"67","author":"Novak","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.mocell.2025.100193_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.mocell.2025.100193_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2019.108497","article-title":"Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer","volume":"152","author":"O'Reilly","year":"2019","journal-title":"Steroids"},{"key":"10.1016\/j.mocell.2025.100193_bib52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","article-title":"Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma","volume":"15","author":"Otto","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.mocell.2025.100193_bib54","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/modpathol.2017.44","article-title":"FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate","volume":"30","author":"Park","year":"2017","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.mocell.2025.100193_bib55","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41586-019-1347-4","article-title":"Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer","volume":"571","author":"Parolia","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.mocell.2025.100193_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2010.05.024","article-title":"Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors","volume":"18","author":"Qi","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib57","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.mocell.2025.100193_bib58","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/emboj.2011.328","article-title":"Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer","volume":"30","author":"Sahu","year":"2011","journal-title":"EMBO J"},{"key":"10.1016\/j.mocell.2025.100193_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.stem.2012.12.007","article-title":"The sox family of transcription factors: versatile regulators of stem and progenitor cell fate","volume":"12","author":"Sarkar","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib60","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41388-019-0997-x","article-title":"SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K\/AKT\/SOX2 axis and beyond","volume":"39","author":"Schaefer","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.mocell.2025.100193_bib61","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mocell.2025.100193_bib62","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1126\/science.7871435","article-title":"The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes","volume":"267","author":"Schoenherr","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.mocell.2025.100193_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.mocell.2025.100193_bib64","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/nar\/gkt921","article-title":"REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer","volume":"42","author":"Svensson","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.mocell.2025.100193_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112937","article-title":"ASCL1 is activated downstream of the ROR2\/CREB signaling pathway to support lineage plasticity in prostate cancer","volume":"42","author":"Tabrizian","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.mocell.2025.100193_bib66","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.3390\/ijms23052588","article-title":"Development of VPC-70619, a small-molecule N-Myc inhibitor as a potential therapy for neuroendocrine prostate cancer","volume":"23","author":"Ton","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mocell.2025.100193_bib67","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/0008-5472.CAN-20-3351","article-title":"Activated ALK Cooperates with N-Myc via Wnt\/\u03b2-catenin signaling to induce neuroendocrine prostate cancer","volume":"81","author":"Unno","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib68","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-017-0593-6","article-title":"Emerging variants of castration-resistant prostate cancer","volume":"19","author":"Vlachostergios","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.mocell.2025.100193_bib69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.mocell.2025.100193_bib70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41585-021-00490-0","article-title":"Molecular events in neuroendocrine prostate cancer development","volume":"18","author":"Wang","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.mocell.2025.100193_bib71","first-page":"4914","article-title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat.\u00a0Commun."},{"key":"10.1016\/j.mocell.2025.100193_bib72","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mocell.2025.100193_bib73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-019-0941-2","article-title":"N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421\/ATM pathway","volume":"18","author":"Yin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mocell.2025.100193_bib74","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1016\/j.clgc.2017.04.006","article-title":"Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis","volume":"15","author":"Zaffuto","year":"2017","journal-title":"Clin. Genitourin Cancer"},{"key":"10.1016\/j.mocell.2025.100193_bib75","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-0157","article-title":"SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mocell.2025.100193_bib76","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41467-020-14318-9","article-title":"Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mocell.2025.100193_bib77","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1158\/0008-5472.CAN-06-0486","article-title":"Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer","volume":"66","author":"Zhou","year":"2006","journal-title":"Cancer Res."}],"container-title":["Molecules and Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1016847825000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1016847825000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T10:04:19Z","timestamp":1741860259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1016847825000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1016847825000172"],"URL":"https:\/\/doi.org\/10.1016\/j.mocell.2025.100193","relation":{},"ISSN":["1016-8478"],"issn-type":[{"value":"1016-8478","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of transcription factors in prostate cancer progression","name":"articletitle","label":"Article Title"},{"value":"Molecules and Cells","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mocell.2025.100193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of Korean Society for Molecular and Cellular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100193"}}